You are free to share (copy and redistribute) this article in any medium or format within the parameters below: Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must ...

The FDA has accepted for Priority Review the New Drug Application for TransCon CNP (navepegritide) for the treatment of children with achondroplasia.

For TransCon CNP treatment-naïve children, mean annualized growth velocity (AGV) was 9.14 cm/year, representing an increase from baseline at Week 26 of 4.23 cm/year, with an improvement in mean ACH ...

Circulating FGF23 (fibroblast growth factor–23) can cross into the brain and influence hypertensive responses and sympathoexcitation after excess phosphate intake. FGF receptor 4 signaling ... mg/g −1 ...

Department of Internal Medicine–Cardiology Division, University of Texas Southwestern Medical Center, Dallas. (H.-K.K., B.A.R., W.V.) Department of Applied Clinical ...

Vietnamese families are having fewer children than ever before. The birth rate in 2021 was 2.11 children per woman, just over the replacement rate required for a population to avoid shrinking over ...

In early-stage estrogen receptor-positive ... cells to drive growth. Mutualistic cancer-fibroblast crosstalk mechanisms, identified from patient samples, were verified across in vitro model systems, ...

Incyte trades -8.61% away from its average analyst target price of $73.88 per share. The 23 analysts following the stock have set target prices ranging from $52.0 to $96.0, and on average have given ...